Bank of America

Chinese detergent maker Blue Moon Group has raised HK$9.8bn ($1.27bn) from its Hong Kong IPO, which saw a strong turnout from global and local investors.

Aroundtown, the Luxembourg-listed real estate company, maintained the trend for negative premiums in December’s buzzing corporate bond market, but syndicate bankers say that any disappointment from the European Central Bank when it meets tomorrow could slam the issuance window shut.

Chinese electric vehicle manufacturer Xpeng is selling a chunk of new American Depository Shares (ADS) to fund research and development and further expansion.

Harbour Biomed has pocketed HK$1.71bn ($220.8m) by pricing its IPO just above the mid point of the marketed range.

Dada Nexus, which operates on-demand retail and delivery platforms in China, raised $450m this week after selling a chunk of new equity.

Blue Moon Group, a Chinese detergent maker, saw the book for its up to HK$9.8bn ($1.3bn) IPO covered within hours of opening on Friday.

The dollar bond market is wide open for companies to take advantage of strong demand and a rally in spreads, boosting hopes for a busy end to a record year for investment grade issuance.

Webuild, the Italian construction company formerly known as Salini Impregilo, has launched a refinancing of its €600m 2021 bond, after finally completing the takeover of stricken competitor Astaldi at the beginning of last month. The new tender offer is intended to finish a refi attempt started in January, which received lacklustre take-up.

GardaWorld, the Canadian security company, made its final pitch for larger UK rival G4S on Wednesday, raising the offer to £3.68bn in a deal that will land the lenders up to £180m in fees.

JD Health International has raised HK$27bn ($3.5bn) after sealing its IPO at the top end of the marketed range, following a flood of global investor demand.

Chinese firm Dada Nexus has launched a follow-on offer of its Nasdaq-listed American depositary shares (ADS). The deal could raise around $521.6m.

China's Harbour Biomed, a clinical-stage biopharmaceutical company, has hit the road for its up to HK$1.8bn ($230.4m) listing.